NKTR: Strong pipeline

Today’s very positive article re: NKTR on S/A:

Nektar Therapeutics (NASDAQ:NKTR) - a bioscience that focuses on the innovation and launch of novel medicines to service cancer, autoimmune disease, and chronic pain - is truly a gift that keeps on giving. Undergoing robust growth, Nektar is powered by various promising fundamental developments.

< snip >

In all, Nektar is brewing an enriched and robust pipeline. The emphasis on combo medicine is a prudent approach toward managing cancers. The recent BMS partnership speaks volume for the substantial prospects in lead molecule NKTR-214 (being studied in 20 different cancer indications). And, we expect most of those franchises to deliver stellar data outcomes and to procure blockbuster sales.

< snip >


long NKTR